SG11201404542TA - Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer - Google Patents

Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer

Info

Publication number
SG11201404542TA
SG11201404542TA SG11201404542TA SG11201404542TA SG11201404542TA SG 11201404542T A SG11201404542T A SG 11201404542TA SG 11201404542T A SG11201404542T A SG 11201404542TA SG 11201404542T A SG11201404542T A SG 11201404542TA SG 11201404542T A SG11201404542T A SG 11201404542TA
Authority
SG
Singapore
Prior art keywords
sorafenib
cancer
compositions
treatment
ndga derivatives
Prior art date
Application number
SG11201404542TA
Other languages
English (en)
Inventor
Ru Chih Huang
David Mold
Christopher Ruland
Yu-Chuan Liang
Jong Ho Chun
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SG11201404542TA publication Critical patent/SG11201404542TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201404542TA 2012-02-03 2013-02-04 Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer SG11201404542TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594743P 2012-02-03 2012-02-03
US201261614825P 2012-03-23 2012-03-23
PCT/US2013/024595 WO2013116821A1 (en) 2012-02-03 2013-02-04 Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201404542TA true SG11201404542TA (en) 2014-10-30

Family

ID=48905944

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404542TA SG11201404542TA (en) 2012-02-03 2013-02-04 Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer

Country Status (8)

Country Link
US (1) US9877978B2 (ja)
EP (1) EP2809308B1 (ja)
JP (1) JP6205373B2 (ja)
CN (1) CN104640538B (ja)
AU (1) AU2013214731B2 (ja)
HK (1) HK1203376A1 (ja)
SG (1) SG11201404542TA (ja)
WO (1) WO2013116821A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017011838A (es) * 2015-03-19 2018-06-06 Univ Northwestern Composiciones y metodos para tratar carcinoma hepatocelular.
CN107753469B (zh) * 2017-09-20 2020-08-04 温州医科大学 Ndga类似物在制备抗氧化药物中的应用
WO2021108601A1 (en) * 2019-11-25 2021-06-03 The Johns Hopkins University Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
AU2005294432A1 (en) * 2004-10-06 2006-04-20 Chih-Chuan Chang Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
JP2009513706A (ja) * 2005-10-31 2009-04-02 バイエル ヘルスケア リミティド ライアビリティ カンパニー ソラフェニブを用いた癌の治療
USRE46907E1 (en) * 2008-01-08 2018-06-26 The Johns Hopkins University Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
CA2742986C (en) * 2008-11-07 2015-03-31 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
CN101536986B (zh) * 2009-04-16 2011-05-04 北京圣医耀科技发展有限责任公司 含索拉非尼的海藻酸钠靶向缓释微球血管栓塞剂及其制备和应用
US9101567B2 (en) * 2010-02-22 2015-08-11 The Johns Hopkins University Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine

Also Published As

Publication number Publication date
JP2015505567A (ja) 2015-02-23
AU2013214731B2 (en) 2017-01-12
WO2013116821A9 (en) 2013-10-17
CN104640538A (zh) 2015-05-20
JP6205373B2 (ja) 2017-09-27
EP2809308A4 (en) 2015-08-19
HK1203376A1 (en) 2015-10-30
EP2809308A1 (en) 2014-12-10
US20150018302A1 (en) 2015-01-15
WO2013116821A1 (en) 2013-08-08
CN104640538B (zh) 2018-01-02
US9877978B2 (en) 2018-01-30
AU2013214731A1 (en) 2014-08-21
EP2809308B1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
IL238177A0 (en) Methods and preparations for the treatment of cancer
HK1203947A1 (en) Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol)
HK1212251A1 (en) Topical compositions and methods of use
EP2961419A4 (en) PHF20 AND JMJD3 COMPOSITIONS AND METHOD FOR USE IN CANCER IMMUNOTHERAPY
HK1209031A1 (en) Polysaccharide compositions and methods of use
IL226095A0 (en) The history of pyridine and its use in pharmaceutical preparations for the treatment of cancer
GB201222455D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
IL233875A (en) Preparation and use for the treatment of anal fissures
EP2958591A4 (en) METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF CANCER
HK1203376A1 (en) Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer ndga
HK1203430A1 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
EP2928456A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
IL233961A0 (en) The composition of a phytogenic supplement and methods of its use
IL245998B (en) Pharmaceutical preparations for the treatment of metastatic cancer and its prevention
SG11201504779YA (en) Methods and compositions relating to treatment of cancer